Active	Status	Sponsor type	Region	Phase	Filter
8 Active 8 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ALLANORE, Yannick
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Active, not recruiting	2/3	301	Europe, Japan, US, RoW	HZN-825 BID, Placebo, HZN-825 QD	Amgen, Horizon Therapeutics USA, Inc	Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic	09/25	09/25
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE	Recruiting	2/3	300	Europe, Japan, US, RoW	Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo	GlaxoSmithKline	Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic	07/27	07/27
SCLERITA, NCT04789850: Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis	Recruiting	2	74	Europe	Itacitinib, Placebo	Assistance Publique - Hôpitaux de Paris	Systemic Sclerosis	02/26	02/26
NCT05626751 / 2021-006271-42: An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)	Enrolling by invitation	2	240	Europe, Japan, US, RoW	HZN-825	Amgen, Horizon Therapeutics USA, Inc, Horizon Therapeuthics USA, Inc	Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic	02/25	02/25
ePRAT, NCT05124782: Virtual Management of Rheumatoid Arthritis	Recruiting	N/A	100	Europe	Rheumatoid Arthritis Impact of Disease questionnaire	Assistance Publique - Hôpitaux de Paris	Rheumatoid Arthritis	11/23	03/24
SHASAR, NCT03716921: Short 3-week Antibiotic Treatment Versus 6 Weeks in Adults With Septic Arthritis of Native Joint	Recruiting	N/A	350	Europe	Short antibiotics treatment, 3-week antibiotic treatment	Assistance Publique - Hôpitaux de Paris	Septic Arthritis	02/24	08/24
SIC2, NCT05424926: Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease	Active, not recruiting	N/A	22	Europe	collection of clinical parameters and blood sample	Assistance Publique - Hôpitaux de Paris	Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis	12/23	02/25
MAJIC, NCT05534347: Angiogenic Biomarkers in Juvenile Idiopathic Arthritis	Recruiting	N/A	300	Europe	Blood sample, Joint puncture	Assistance Publique - Hôpitaux de Paris	Juvenile Idiopathic Arthritis (JIA)	03/30	03/30